Skip to main content

Advertisement

Table 1 Characteristics of patients with or without observed initiation of BOT (continuous variables)

From: Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry

Covariate Total population BOT(observed) BOT(not observed) MD (95 % CI)
(N = 31,008) (N = 6,705) (N = 24,303)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 62.4 (3.5) 62.4 (3.4) 62.5 (3.5) −0.05 (−0.36, 0.26)
BMI (kg/m2) 32.4 (2.6) 33.0 (2.5) 32.2 (2.6) 0.7 (0.52, 0.93)
Weight (kg) 93.2 (4.6) 95.2 (4.6) 92.6 (4.6) 2.6 (1.9, 3.23)
Diabetes duration (years) 8.2 (2.7) 10.6 (2.8) 7.5 (2.7) 3.1 (2.86, 3.31)
HbA1c (%) 7.5 (1.2) 8.0 (1.2) 7.4 (1.2) 0.6 (0.55, 0.65)
FPG (mmol/l) 8.1 (1.5) 8.7 (1.6) 8.0 (1.5) 0.7 (0.58, 0.78)
PPG (mmol/l)a 9.5 (4.7) 10.8 (4.3) 9.1 (4.7) 0.9 (0.70, 1.14)
  1. Legend: BOT basal supported oral therapy, MD mean difference, BMI body mass index, HbA1c glycated haemoglobin, FPG fasting plasma glucose, PPG postprandial plasma glucose. Confidence intervals (CIs) for the mean difference were derived by Welch’s t-tests
  2. abased on the available data: N = 7,382 (Total), 1,635 (BOT(observed)), 5,747 (BOT(not observed))